A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.

A de Agostini; P A Patston; V Marottoli; S Carrel; P C Harpel; M Schapira

doi:10.1172/JCI113650

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by de Agostini, A. in: PubMed | Google Scholar

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by Patston, P. in: PubMed | Google Scholar

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by Marottoli, V. in: PubMed | Google Scholar

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by Carrel, S. in: PubMed | Google Scholar

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by Harpel, P. in: PubMed | Google Scholar

Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232.

Find articles by Schapira, M. in: PubMed | Google Scholar

Published in Volume 82, Issue 2 on August 1, 1988
J Clin Invest. 1988;82(2):700–705. https://doi.org/10.1172/JCI113650.
© 1988 The American Society for Clinical Investigation

Published August 1, 1988 - Version history

The reactive center of C1-inhibitor, a plasma protease inhibitor that belongs to the serpin superfamily, is located on a peptide loop which is highly susceptible to proteolytic cleavage. With plasma kallikrein, C1s and beta-Factor XIIa, this cleavage occurs at the reactive site residue P1 (Arg444); with neutrophil elastase, it takes place near P1, probably at residue P3 (Val442). After these cleavages, C1-inhibitor is inactivated and its conformation is modified. Moreover, in vivo, cleaved C1-inhibitor is removed from the blood stream more rapidly than the intact serpin, which suggests that proteolysis unmasks sites responsible for cellular recognition and the uptake of the cleaved inhibitor. In the study reported here, we show, using an MAb, that an identical neoepitope is created on C1-inhibitor after the cleavage of its exposed loop by plasma kallikrein, C1s, beta-Factor XIIa, and by neutrophil elastase.

Images.